Instant Clot-Forming and Antibacterial Dressings: Integrating Tranexamic Acid in Trauma Care

Study Background and Research Question

Uncontrolled hemorrhage and wound infection remain leading causes of death following traumatic injuries, accounting for a significant portion of early mortality among both civilians and military personnel. Traditional wound dressings often fall short in providing both rapid hemostasis and robust infection control, particularly in austere or pre-hospital settings. Nitric oxide (NO) has emerged as a promising agent due to its multifaceted roles in wound healing, including antimicrobial activity, modulation of inflammation, and promotion of tissue repair. Tranexamic acid, a synthetic antifibrinolytic agent, is established in clinical settings for stabilizing clots and reducing bleeding, but its integration into advanced wound dressings for instant clot formation has not been fully realized. The central question addressed by the reference study is whether a wound dressing can be engineered to provide both immediate hemostasis and effective antibacterial protection by co-delivering tranexamic acid and NO within a rationally designed biomaterial scaffold.

Key Innovation from the Reference Study

The study introduces a novel bi-layer wound dressing, termed T-SP, which combines the clot-stabilizing effect of tranexamic acid (TXA), the antibacterial properties of nitric oxide (NO) released from the donor S-nitroso-N-acetylpenicillamine (SNAP), and the bioadhesive, anti-inflammatory attributes of propolis. The innovation lies in the spatially controlled delivery: TXA is localized at the wound-contacting surface embedded within a propolis resin, while SNAP is incorporated in the base layer, embedded in a Carbosil® polymer matrix. This configuration allows for an immediate antifibrinolytic effect at the wound interface to rapidly stabilize clots, while the NO release from the underlying layer provides sustained antibacterial activity. The strategic layering ensures that each component is released where its function is most needed, addressing both excessive blood loss and infection risk in a single platform.

Methods and Experimental Design Insights

The research team fabricated T-SP dressings by first preparing bi-layer films with distinct compositions. The wound-contacting layer consisted of propolis resin loaded with varying concentrations of TXA (2.5%, 5.0%, and 7.5% by volume), while the sub-layer incorporated SNAP in a Carbosil® copolymer. Key in vitro assays included:

• Fibrin clot formation and stability: Platelet adhesion and clot formation were evaluated using a lactate dehydrogenase-based assay. The density and structure of fibrin networks were further visualized by scanning electron microscopy (SEM).
• Antibacterial activity: Quantitative assays measured reductions in colony-forming units (CFUs) of Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii after exposure to the dressing.
• Material characterization: Layer uniformity, NO release kinetics, and the distribution of active agents were assessed to ensure reproducibility and functional separation of clotting and antimicrobial effects.

Protocol Parameters

• Tranexamic acid loading: 2.5%, 5.0%, and 7.5% volume fractions embedded in propolis resin for the wound-contact layer.
• NO donor (SNAP) concentration: Optimized for sustained release in the Carbosil® base layer; precise values tailored to maintain antibacterial levels over the acute wound phase.
• Fibrin activation assay: Platelet-rich plasma applied to dressing for 15 minutes; LDH release quantified for clotting assessment.
• SEM imaging: Samples fixed post-assay and imaged to confirm fibrin architecture.
• Antibacterial efficacy: Bacterial suspensions incubated with dressings for defined periods; CFUs enumerated to quantify reduction rates.

Core Findings and Why They Matter

The T-SP dressings demonstrated a rapid increase in clot formation and stability at the wound interface, with the 7.5% propolis-TXA formulation showing the highest fibrin activation within 15 minutes of application. SEM analysis confirmed the formation of dense fibrin networks, indicating effective inhibition of fibrinolysis and stabilization of the clot—outcomes directly attributable to the antifibrinolytic action of tranexamic acid. Antibacterial testing revealed a 98.9 ± 1% reduction in S. aureus and a 99.4 ± 1% reduction in multidrug-resistant A. baumannii CFUs, highlighting the synergistic effects of NO and propolis in suppressing both common and resistant wound pathogens. These results position the T-SP dressing as a promising solution for emergency trauma care, offering both rapid bleeding time reduction and robust infection control according to the reference study.

Comparison with Existing Internal Articles

Several recent reviews and workflow articles emphasize the role of tranexamic acid as a core antifibrinolytic agent for both clinical and preclinical hemostasis research. For instance, "Tranexamic Acid: Antifibrinolytic Agent for Rapid Hemostasis" and "Tranexamic Acid: Antifibrinolytic Agent for Hemostasis Research" both underscore how TXA acts by competitively inhibiting plasminogen activation, thereby stabilizing blood clots in trauma models and wound assays. However, these articles primarily focus on TXA in isolation or within systemic/topical applications. The reference study extends this knowledge by demonstrating the efficacy of TXA when embedded in a bioactive wound dressing, working in concert with NO-releasing and natural antibacterial agents. This layered, combinatorial approach represents a significant methodological advance over single-agent dressings, providing a blueprint for multifunctional biomaterials in hemorrhage and infection management. For researchers interested in protocol optimization, "Tranexamic Acid in Fibrinolysis Research: Applied Protocols & Innovations" offers further insights into integrating TXA in advanced in vitro and translational workflows.

Limitations and Transferability

While the T-SP dressing shows impressive in vitro performance, several limitations must be acknowledged. The experiments were conducted under controlled laboratory conditions; thus, real-world variables such as wound biomechanics, presence of multiple pathogens, and fluctuating physiological environments were not fully captured. Additionally, the durability and biocompatibility of the composite materials in long-term wound settings require further investigation. The transferability of results to clinical or field use will depend on scalability of fabrication, regulatory approval, and comprehensive in vivo validation. Potential interactions between the propolis resin, NO donor, and tranexamic acid under dynamic conditions also warrant more detailed mechanistic studies.

Research Support Resources

Researchers seeking to replicate or extend these findings in clot formation, inhibition of fibrinolysis, or plasmin-induced neutrophil adherence assays can utilize high-purity Tranexamic Acid (SKU B1858) from APExBIO, which is offered with detailed quality control data and supports reproducible antifibrinolytic workflows. The product's well-defined solubility and IC50 characteristics make it suitable for dose-dependent studies of fibrinolysis and bleeding time reduction in both in vitro and in vivo models. For further reading on protocol design and mechanistic applications, internal resources such as "Mechanistic Insights for Advanced Fibrinolysis Research" and "Reliable Antifibrinolytic for Lab Assays" provide practical guidance on leveraging Tranexamic Acid for advanced hemostasis and wound healing studies.